Abstract
Meeting abstracts The clinical efficacy of tumor specific effector T cells is limited by their proper trafficking to the site of the tumor and the locally immunosuppressive environment. Strategies to improve homing and activity of immune effector cells to tumors are needed to unlock the potential
Highlights
The clinical efficacy of tumor specific effector T cells is limited by their proper trafficking to the site of the tumor and the locally immunosuppressive environment
B16F10-OVA melanoma bearing C57BL/6 mice were immunized with the lentiviral vector DCVex on 10 days after tumor challenge to induce OVA specific effector and memory CD8 T cells
Tumors were excised, homogenized, and the number and phenotype of OVA-specific infiltrating lymphocytes were analyzed via flow cytometry by staining cells with phenotyping cell surface markers and OVA-pentamers
Summary
A “prime-pull” immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells. Tina C Albershardt*, Andrea J Parsons, Patrick Flynn, Peter Berglund, Jan ter Meulen. From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
